Performance Characteristics of 5 Immunoassays for SARS-CoV-2
2020
SARS-CoV-2 antibodies typically start to appear at least 5–7 days post infection and are therefore an unreliable marker for early acute infection. The degree and duration of immunity that antibodies confer are unclear. A prominent use for serological testing has therefore been at a population level, for informing the extent of population exposure.
Immunoassays used for SARS-CoV-2 testing detect either specific types of antibody (e.g., IgM or IgG) or total antibody. To date, few thorough, direct assessments of immunoassay performance on large sample sets have been done. In this study, a head-to-head assessment of five immunoassays was done. The study found that four commercial, widely available assays and a scalable 384-well ELISA can be used for SARS-CoV-2 serological testing to achieve sensitivity and specificity of at least 98%.
Adapted from publication abstract.
Performance Characteristics of 5 Immunoassays for SARS-CoV-2
Source:
The National SARS-CoV-2 Serology Assay Evaluation Group. Performance Characteristics of Five Immunoassays for SARS-CoV-2: A Head-to-Head Benchmark Comparison. The Lancet Infectious Diseases 2020; 20 (12): 1390-1400. https://doi.org/10.1016/S1473-3099(20)30634-4